News

Updated: Exciting News for Patients with Grade 2 Oligodendroglioma and Astrocytoma UPDATED (August 6, 2024): The U.S. Food and Drug Administration (FDA) has approved vorasidenib (brand name: Voranigo) for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. This is […] August 6, 2024

New Approval of Treatment for Young Children with Certain Brain Cancers On March 16, 2023, the U.S. Food and Drug Administration approved a new treatment combination that will now be available as an option for pediatric patients 1 year of age and older with low-grade glioma (LGG, grade 1 or 2) that have a mutation called BRAF V600E. This marks the first FDA approval of a […] March 21, 2023

New Brain Tumor Clinical Trials: July- December 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for patients with a primary brain tumor*. Follow the hyperlink above to learn more about […] January 20, 2023

Q&A: A New Treatment Approved for Certain Brain Tumors In late June 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The approved combination of two oral drugs, called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist), is for the treatment of advanced tumors […] August 9, 2022

New Brain Tumor Clinical Trials: January – June 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the […] July 5, 2022